Skip to main content
HUMDF logo

Hua Medicine (Shanghai) Ltd. (HUMDF) Stock Price & Analysis

Hua Medicine (Shanghai) Ltd. (HUMDF) — price $0.3036 (0.00%), as of the Nov 19, 2026 trading session; market cap $303M.

Educational signal · not a buy or sell recommendation · How to read this

$0.3036 $0.00 (0.00%) Market Cap $303M

Hua Medicine (Shanghai) Ltd. · HUMDF

Hua Medicine (Shanghai) Ltd. is a clinical-stage drug development company focused on therapies for diabetes in China.

Price as of Nov 19, 2026

Key Statistics

Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.

Thousands of the 20,000+ US stocks here carry a MoonshotScore.

Scored companies in the same industry:

  • SNDL · SNDL Inc. · 32 /100
  • TLRY · Tilray Brands, Inc. · 20 /100
  • ACB · Aurora Cannabis Inc. · 19 /100

See all scored stocks →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$0.3036
Change on the day0.00%
Market capitalisation$303M
Price / earnings (trailing)1.75
Shares traded on the day1.0K

Price & events

Other perspectives

Council score for Hua Medicine (Shanghai) (HUMDF): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Legends Council

4 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Favorable read

Read on: Nov 14, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Weak
Margin of Safety Fairly Valued
Profit Margin Weak
Revenue Growth Strong
Debt/Equity Neutral
ROE Strong
Gross Margin Strong

Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Sep 10, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Hua Medicine (Shanghai) (HUMDF), and what does it report?

Short answer · as of

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Hua Medicine (Shanghai) Ltd. (HUMDF) is the company analyzed here. It employs 424 people. In Q2 FY2026 it reported revenue of CN¥374M and net income of -CN¥30M. The market values it at $303M.

2 · Latest results

What do the latest results show for Hua Medicine (Shanghai) (HUMDF)?

Short answer · as of

The most recent reported quarter, Q2 FY2026, carried revenue of CN¥374M. Against analyst estimates the company has EPS beat 5 of the last 8 reports.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q2 FY2026CN¥374M-CN¥30M-CN¥0.03 (diluted)
Q4 FY2025CN¥271M-CN¥76M-CN¥0.07 (diluted)
Q2 FY2025CN¥217MCN¥1.18BCN¥1.20 (diluted)
Q4 FY2024CN¥153M-CN¥108M-CN¥0.11 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Hua Medicine (Shanghai) (HUMDF)?

Short answer · as of

The distress and quality screens read Altman Z -1.62 · Piotroski F 4. Trailing ratios: ROE -10.6% · ROA -7.0% · current ratio 3.34 · earnings yield -5.7% · free-cash-flow yield -2.0%.

Data-derived red flags

  • Financial-distress signal — its Altman Z-Score of -1.62 sits in the distress zone (elevated bankruptcy risk).
  • Negative return on equity (-10.6%) — the business is not currently generating profit on shareholder capital.

The records behind this page

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held HUMDF in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported HUMDF in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

Common Questions About HUMDF

These answers are editorial: 1 of these 8 answers is drawn from the HUMDF research dossier (written Mar 15, 2026 by gemini-2.0-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.

Is HUMDF a good stock to buy?

Stock Expert AI does not rate HUMDF buy, sell or hold. Hua Medicine (Shanghai) Ltd. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the HUMDF stock price today?

The last price recorded for Hua Medicine (Shanghai) Ltd. (HUMDF), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What do analysts say about HUMDF stock?

Analyst coverage of HUMDF is limited due to its OTC listing and clinical-stage nature. Key valuation metrics to consider include the potential market size for Dorzagliatin in China, the probability of successful clinical trial outcomes, and the regulatory pathway for drug approval.

What are the key factors to evaluate for HUMDF?

Evaluate HUMDF on fundamentals, analyst consensus, and risk factors. To weigh it, start with the trailing P/E under Price & valuation on this page. This can provide access to additional funding, expertise, and distribution channels. Not financial advice.

How frequently does HUMDF data refresh on this page?

HUMDF's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven HUMDF's recent stock price performance?

Hua Medicine (Shanghai) Ltd. (HUMDF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Novel drug candidate (Dorzagliatin) with a unique mechanism of action. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider HUMDF overvalued or undervalued right now?

The trailing P/E of Hua Medicine (Shanghai) Ltd. (HUMDF) is listed under Price & valuation on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

How do I research HUMDF before investing?

Before investing in Hua Medicine (Shanghai) Ltd. (HUMDF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 13 figures on this page — 10 from Financial Modeling Prep (FMP) and 3 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.